IL129237A0 - Use of mupirocin for the manufacture of a medicament for the treatment of bacterial infections associated with colonisation of the nasopharynx by pathogenic organisms - Google Patents

Use of mupirocin for the manufacture of a medicament for the treatment of bacterial infections associated with colonisation of the nasopharynx by pathogenic organisms

Info

Publication number
IL129237A0
IL129237A0 IL12923797A IL12923797A IL129237A0 IL 129237 A0 IL129237 A0 IL 129237A0 IL 12923797 A IL12923797 A IL 12923797A IL 12923797 A IL12923797 A IL 12923797A IL 129237 A0 IL129237 A0 IL 129237A0
Authority
IL
Israel
Prior art keywords
colonisation
mupirocin
nasopharynx
medicament
manufacture
Prior art date
Application number
IL12923797A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9716805.8A external-priority patent/GB9716805D0/en
Priority claimed from GBGB9719203.3A external-priority patent/GB9719203D0/en
Application filed by Smithkline Beecham Corp, Smithkline Beecham Plc filed Critical Smithkline Beecham Corp
Publication of IL129237A0 publication Critical patent/IL129237A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL12923797A 1996-10-01 1997-09-29 Use of mupirocin for the manufacture of a medicament for the treatment of bacterial infections associated with colonisation of the nasopharynx by pathogenic organisms IL129237A0 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US2722396P 1996-10-01 1996-10-01
US2722296P 1996-10-01 1996-10-01
US2722496P 1996-10-01 1996-10-01
GBGB9716805.8A GB9716805D0 (en) 1997-08-09 1997-08-09 Novel composition and use
GBGB9719203.3A GB9719203D0 (en) 1997-09-11 1997-09-11 Novel composition and use
PCT/GB1997/002664 WO1998014189A1 (en) 1996-10-01 1997-09-29 Use of mupirocin for the manufacture of a medicament for the treatment of bacterial infections associated with colonisation of the nasopharynx by pathogenic organisms

Publications (1)

Publication Number Publication Date
IL129237A0 true IL129237A0 (en) 2000-02-17

Family

ID=27517419

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12923797A IL129237A0 (en) 1996-10-01 1997-09-29 Use of mupirocin for the manufacture of a medicament for the treatment of bacterial infections associated with colonisation of the nasopharynx by pathogenic organisms

Country Status (17)

Country Link
US (1) US6001870A (no)
EP (1) EP0939631A1 (no)
JP (1) JP2001504091A (no)
KR (1) KR20000048812A (no)
CN (1) CN1239427A (no)
AR (1) AR010995A1 (no)
AU (1) AU724070B2 (no)
BR (1) BR9711843A (no)
CA (1) CA2267248A1 (no)
CZ (1) CZ112499A3 (no)
HU (1) HUP9904308A3 (no)
IL (1) IL129237A0 (no)
NO (1) NO991548L (no)
NZ (1) NZ334913A (no)
PL (1) PL332642A1 (no)
TR (1) TR199900733T2 (no)
WO (1) WO1998014189A1 (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001504091A (ja) * 1996-10-01 2001-03-27 スミスクライン・ビーチャム・コーポレイション 病原性生物による鼻咽腔のコロニー形成に関連する細菌感染の治療のための薬剤の製造のためのミュピロシンの使用
CO4910145A1 (es) 1996-10-01 2000-04-24 Smithkline Beecham Corp Uso
CA2299298A1 (en) * 1997-08-09 1999-02-18 Jane Elizabeth Hilton Compositions for nasal administration
UY25225A1 (es) 1997-10-29 2000-12-29 Smithkline Beecham Plc Derivados de pleuromutilina utiles como agentes antimicrobianos
GB9808470D0 (en) 1998-04-22 1998-06-17 Smithkline Beecham Plc Novel process and apparatus
GB9902138D0 (en) 1999-02-02 1999-03-24 Smithkline Beecham Container
US6509177B1 (en) * 1999-02-03 2003-01-21 Biogal Gyogyszergyar Rt. Process for the preparation of pseudomonic acid A antibiotic by microbiological method
EP1185246A1 (de) * 1999-06-02 2002-03-13 Klöcker, Norbert, Dr.med. Pharmazeutische zusammmensetzung zur nasalen anwendung von wasserunlöslichen und/oder schwer wasserlöslischen wirkstoffen
US6676930B2 (en) * 1999-11-28 2004-01-13 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
US6156294A (en) * 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
TR200403211T3 (tr) * 2001-06-21 2005-02-21 Biogal Gyogyszergyar Rt Psödomonik asit üretimi için metabolik olarak kontrol edilen fermantasyon işlemi.
EP1455769A4 (en) 2001-12-28 2004-09-22 Biogal Gyogyszergyar METHOD FOR PRODUCING CRYSTALLINE AND AMORPHIC MUPIROCIN CALCIUM
US20050058673A1 (en) 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
DK1641438T3 (da) * 2004-06-01 2010-06-07 Teva Gyogyszergyar Zartkoeruen Fremgangsmåde til fremstilling af den amorfe form af et lægemiddel
BRPI0608691A2 (pt) 2005-03-10 2010-12-07 3M Innovative Properties Co composição antimicrobiana, e, métodos para matar ou inativar microorganismos em tecido da mucosa de um mamìfero, para tratar uma lesão ou ferimento infectado, para descolonização de microorganismos, para proporcionar eficácia antimicrobiana residual sobre uma superfìcie e para tratar uma condição
US8476319B2 (en) * 2005-03-10 2013-07-02 3M Innovative Properties Company Methods of treating ear infections
EP1858482B1 (en) 2005-03-10 2014-04-23 3M Innovative Properties Company Methods of reducing microbial contamination
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
US20070264296A1 (en) 2006-05-10 2007-11-15 Myntti Matthew F Biofilm extracellular polysachharide solvating system
US7959943B2 (en) 2006-05-10 2011-06-14 Medtronics Xomed, Inc. Solvating system and sealant for medical use in the middle or inner ear
US7976873B2 (en) 2006-05-10 2011-07-12 Medtronic Xomed, Inc. Extracellular polysaccharide solvating system for treatment of bacterial ear conditions
US7993675B2 (en) 2006-05-10 2011-08-09 Medtronic Xomed, Inc. Solvating system and sealant for medical use in the sinuses and nasal passages
US8088095B2 (en) 2007-02-08 2012-01-03 Medtronic Xomed, Inc. Polymeric sealant for medical use
AU2009257390B2 (en) 2008-06-12 2014-09-04 Medtronic Xomed, Inc. Method for treating chronic wounds with an extracellular polymeric substance solvating system
US20100021563A1 (en) * 2008-07-24 2010-01-28 Paul Levesque Compositions comprising coconut oil and methods of use thereof
WO2010042427A2 (en) 2008-10-06 2010-04-15 Microbial Defense Systems, Llc Antimicrobial composition and methods of making and using same
JP6463629B2 (ja) 2011-05-10 2019-02-06 ネクスト サイエンス アイピー ホールディングス ピーティワイ エルティーディ 抗菌性固体およびその製造方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ200918A (en) * 1981-07-02 1985-07-31 Gist Brocades Nv Stable fatty oil-in-water emulsion cream for topical application
CA1196284A (en) * 1982-05-28 1985-11-05 Joshua Oduro-Yeboah Pharmaceutical formulations
SE8206744D0 (sv) * 1982-11-26 1982-11-26 Fluidcarbon International Ab Preparat for kontrollerad avgivning av substanser
GB8415579D0 (en) * 1984-06-19 1984-07-25 Beecham Group Plc Compounds
GB8530796D0 (en) * 1985-12-13 1986-01-22 Beecham Group Plc Pharmaceutical composition
IE59628B1 (en) * 1986-06-26 1994-03-09 Beecham Group Plc Treatment of fungal infections
US5594026A (en) * 1990-12-11 1997-01-14 Smithkline Beecham Group P.L.C. Polymorphs of crystalline mupirocin
PL177592B1 (pl) * 1993-10-22 1999-12-31 Smithkline Beecham Corp Kompozycja farmaceutyczna lub weterynaryjna w postaci kremu
JP2001504091A (ja) * 1996-10-01 2001-03-27 スミスクライン・ビーチャム・コーポレイション 病原性生物による鼻咽腔のコロニー形成に関連する細菌感染の治療のための薬剤の製造のためのミュピロシンの使用

Also Published As

Publication number Publication date
NO991548D0 (no) 1999-03-30
PL332642A1 (en) 1999-09-27
AR010995A1 (es) 2000-08-02
CN1239427A (zh) 1999-12-22
NO991548L (no) 1999-03-31
EP0939631A1 (en) 1999-09-08
AU4562397A (en) 1998-04-24
AU724070B2 (en) 2000-09-14
HUP9904308A2 (hu) 2001-04-28
BR9711843A (pt) 2001-07-31
KR20000048812A (ko) 2000-07-25
CZ112499A3 (cs) 1999-08-11
HUP9904308A3 (en) 2002-06-28
WO1998014189A1 (en) 1998-04-09
TR199900733T2 (xx) 1999-07-21
US6001870A (en) 1999-12-14
CA2267248A1 (en) 1998-04-09
NZ334913A (en) 2001-03-30
JP2001504091A (ja) 2001-03-27

Similar Documents

Publication Publication Date Title
IL129237A0 (en) Use of mupirocin for the manufacture of a medicament for the treatment of bacterial infections associated with colonisation of the nasopharynx by pathogenic organisms
NZ506058A (en) Antibacterial 9-substituted tetracyclines, and pharmaceuticals and uses thereof
WO2001045679A3 (de) Verwendung von chemotherapeutika zur topischen behandlung
GB0125222D0 (en) Composition for the treatment of microbial infections
HK1014160A1 (en) Anti-gram-positive bacterial methods and materials
SI0789025T1 (en) Substituted oxazolidinone and their use as antibacterial medicine
EP0326891A3 (en) Antibacterial agents
IL230875A0 (en) The use of delvavancin in a pharmaceutical carrier is accepted in the production of a drug for the treatment of bacterial infections
PT102450A (pt) Formulacao farmaceutica de libertacao modificada compreendendo amoxicilina e clavulanato de potassio e utilizacao destes compostos no fabrico de um medicamento para o tratamento de infeccoes bacterianas
IL146255A0 (en) Attenuated microorganisms for the treatment of infection
AU2000255628A1 (en) Formulation comprising thymol useful in the treatment of drug resistant bacterial infections
CA2267309A1 (en) Use of 1-hydroxy-2-pyridones for the treatment of skin infections
FR2782093B1 (fr) Procede de preparation de cultures de bacteries lactiques
CA2380455A1 (en) 9a-azalides with antibacterial activity
PT1227827E (pt) Bacterias acido-lacticas para o tratamento e/ou profilaxia da giardiase
PL371524A1 (en) Combination therapy for the treatment of bacterial infections
EP1618106A4 (en) CARBACEPHEM LACTAM ANTIBIOTICS
HK1052643A1 (en) Use of pleuromutilin derivatives in the manufacture of a mediament for transdermal treatment of bacterial infections in humans and animals
NZ509051A (en) Chemotaxis-inhibiting protein of staphylococcus (CHIPS) and its use
MY104109A (en) Antibacterial 9-deoxo-9a-allyl and propargyl-9a-aza-9a-homoerythromycin a derivatives.
EP2250887A3 (en) Use of non-antibacterial tetracycline analog CMT-1002 and formulations thereof for the treatment of bacterial exotoxins
HK1046913A1 (zh) 為治療傳染病的被縮小微生物
CA2468036A1 (en) A method of treating bacterial infections using gemifloxacin or a salt thereof and a .beta.-lactam antibiotic
AU3333695A (en) Methods and products for the control of pathogenic bacteria
HK1022420A1 (en) The use of homocysteine derivatives for the treatment of bacterial infections.